Anika Therapeutics (ANIK) Reports Q1 Loss, Misses Revenue Estimates

Company Performance - Anika Therapeutics reported a quarterly loss of $0.06 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, representing an earnings surprise of -166.67% [1] - The company posted revenues of $26.17 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 8.50%, and a significant decline from year-ago revenues of $40.52 million [2] - Over the last four quarters, Anika has not surpassed consensus EPS estimates and has topped consensus revenue estimates only twice [2] Stock Outlook - Anika shares have declined approximately 10.5% since the beginning of the year, compared to a decline of -3.7% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $0.08 on revenues of $28.23 million, and for the current fiscal year, it is $0.31 on revenues of $113 million [7] - The estimate revisions trend for Anika is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Anika belongs, is currently in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Anika's stock performance [5]